Literature DB >> 31943689

Hepatocellular carcinoma surveillance, early detection and survival in a privately insured US cohort.

Vincent L Chen1, Amit G Singal2, Elliot B Tapper1,3, Neehar D Parikh1.   

Abstract

BACKGROUND/AIMS: Semiannual hepatocellular carcinoma (HCC) surveillance is recommended in patients with cirrhosis; however, recent studies have raised questions over its utility. We investigated the impact of surveillance on early detection and survival in a nationally representative database.
METHODS: We included patients with cirrhosis and HCC from the Optum database (2001-2015) with >6 months of follow-up between cirrhosis and HCC diagnoses. Surveillance adherence was defined as proportion of time covered (PTC), with each 6-month period after abdominal imaging defined as 'covered'. To determine the association between surveillance and mortality, we compared PTC between fatal and non-fatal HCC.
RESULTS: Of 1001 patients with cirrhosis and HCC, 256 died with median follow-up 30 months. Median PTC by any imaging was greater in early-stage vs late-stage HCC (43.6% vs 37.4%, P = .003) and non-fatal vs fatal HCC (40.8% vs 34.3%, P = .001). In multivariable analyses, each 10% increase in PTC was associated with increased early HCC detection (OR 1.07, 95% CI 1.01-1.12) and decreased mortality (HR 0.95; 95% CI 0.90-1.00). On subgroup analysis, PTC by CT/MRI was associated with early tumour detection and decreased mortality; however, PTC by ultrasound was only associated with early detection but not decreased mortality. These findings were robust across sensitivity analyses.
CONCLUSIONS: In a US cohort of privately insured HCC patients, PTC by any imaging modality was associated with increased early detection and decreased mortality. Continued evaluation of HCC surveillance strategies and effectiveness is warranted.
© 2020 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.

Entities:  

Keywords:  Optum; liver cancer; screening

Year:  2020        PMID: 31943689      PMCID: PMC8047296          DOI: 10.1111/liv.14379

Source DB:  PubMed          Journal:  Liver Int        ISSN: 1478-3223            Impact factor:   5.828


  39 in total

Review 1.  Asia-Pacific clinical practice guidelines on the management of hepatocellular carcinoma: a 2017 update.

Authors:  Masao Omata; Ann-Lii Cheng; Norihiro Kokudo; Masatoshi Kudo; Jeong Min Lee; Jidong Jia; Ryosuke Tateishi; Kwang-Hyub Han; Yoghesh K Chawla; Shuichiro Shiina; Wasim Jafri; Diana Alcantara Payawal; Takamasa Ohki; Sadahisa Ogasawara; Pei-Jer Chen; Cosmas Rinaldi A Lesmana; Laurentius A Lesmana; Rino A Gani; Shuntaro Obi; A Kadir Dokmeci; Shiv Kumar Sarin
Journal:  Hepatol Int       Date:  2017-06-15       Impact factor: 6.047

2.  Emerging trends in hepatocellular carcinoma incidence and mortality.

Authors:  Basile Njei; Yaron Rotman; Ivo Ditah; Joseph K Lim
Journal:  Hepatology       Date:  2014-11-24       Impact factor: 17.425

3.  Ethnic disparities and liver transplantation rates in hepatocellular carcinoma patients in the recent era: results from the Surveillance, Epidemiology, and End Results registry.

Authors:  Robert J Wong; Pardha Devaki; Long Nguyen; Ramsey Cheung; Mindie H Nguyen
Journal:  Liver Transpl       Date:  2014-02-25       Impact factor: 5.799

4.  Downstaging of hepatocellular cancer before liver transplant: long-term outcome compared to tumors within Milan criteria.

Authors:  Francis Y Yao; Neil Mehta; Jennifer Flemming; Jennifer Dodge; Bilal Hameed; Oren Fix; Ryutaro Hirose; Nicholas Fidelman; Robert K Kerlan; John P Roberts
Journal:  Hepatology       Date:  2015-03-20       Impact factor: 17.425

5.  Global trends and predictions in hepatocellular carcinoma mortality.

Authors:  Paola Bertuccio; Federica Turati; Greta Carioli; Teresa Rodriguez; Carlo La Vecchia; Matteo Malvezzi; Eva Negri
Journal:  J Hepatol       Date:  2017-03-21       Impact factor: 25.083

6.  Hepatocellular Carcinoma Surveillance Among Cirrhotic Patients With Commercial Health Insurance.

Authors:  David S Goldberg; Adriana Valderrama; Rajesh Kamalakar; Sujit S Sansgiry; Svetlana Babajanyan; James D Lewis
Journal:  J Clin Gastroenterol       Date:  2016-03       Impact factor: 3.062

7.  Hepatocellular Carcinoma Screening Is Associated With Increased Survival of Patients With Cirrhosis.

Authors:  Debra T Choi; Hye-Chung Kum; Sulki Park; Robert L Ohsfeldt; Yu Shen; Neehar D Parikh; Amit G Singal
Journal:  Clin Gastroenterol Hepatol       Date:  2018-10-26       Impact factor: 11.382

8.  Use of administrative claims data for identifying patients with cirrhosis.

Authors:  Mahendra S Nehra; Ying Ma; Christopher Clark; Ruben Amarasingham; Don C Rockey; Amit G Singal
Journal:  J Clin Gastroenterol       Date:  2013 May-Jun       Impact factor: 3.062

9.  Randomized controlled trial of screening for hepatocellular carcinoma.

Authors:  Bo-Heng Zhang; Bing-Hui Yang; Zhao-You Tang
Journal:  J Cancer Res Clin Oncol       Date:  2004-07       Impact factor: 4.553

10.  MRI With Liver-Specific Contrast for Surveillance of Patients With Cirrhosis at High Risk of Hepatocellular Carcinoma.

Authors:  So Yeon Kim; Jihyun An; Young-Suk Lim; Seungbong Han; Ji-Young Lee; Jae Ho Byun; Hyung Jin Won; So Jung Lee; Han Chu Lee; Yung Sang Lee
Journal:  JAMA Oncol       Date:  2017-04-01       Impact factor: 31.777

View more
  2 in total

1.  Effects of Cirrhosis and Diagnosis Scenario in Metabolic-Associated Fatty Liver Disease-Related Hepatocellular Carcinoma.

Authors:  Vincent L Chen; Ming-Lun Yeh; Ju Dong Yang; Jennifer Leong; Daniel Q Huang; Hidenori Toyoda; Yao-Li Chen; Jennifer Guy; Mayumi Maeda; Pei-Chien Tsai; Chung-Feng Huang; Satoshi Yasuda; An K Le; Hansen Dang; Nasra H Giama; Hamdi A Ali; Ning Zhang; Xiaozhong Wang; Dae Won Jun; Cheng-Hao Tseng; Yao-Chun Hsu; Jee-Fu Huang; Chia-Yen Dai; Wan-Long Chuang; Qiang Zhu; Yock Young Dan; Myron Schwartz; Lewis R Roberts; Ming-Lung Yu; Mindie H Nguyen
Journal:  Hepatol Commun       Date:  2020-09-24

2.  Patient Preferences for Hepatocellular Carcinoma Surveillance Parameters.

Authors:  Sean A Woolen; Amit G Singal; Matthew S Davenport; Jonathan P Troost; Shokoufeh Khalatbari; Sukul Mittal; Sehar Siddiqui; Austin Fobar; Jason Morris; Mobolaji Odewole; Elliot B Tapper; Anjana Pillai; Neehar D Parikh
Journal:  Clin Gastroenterol Hepatol       Date:  2021-02-19       Impact factor: 13.576

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.